Joachim Drevs

5.0k total citations
75 papers, 3.4k citations indexed

About

Joachim Drevs is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Joachim Drevs has authored 75 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Molecular Biology, 37 papers in Oncology and 27 papers in Cancer Research. Recurrent topics in Joachim Drevs's work include Angiogenesis and VEGF in Cancer (36 papers), Cancer Treatment and Pharmacology (20 papers) and Cancer, Hypoxia, and Metabolism (16 papers). Joachim Drevs is often cited by papers focused on Angiogenesis and VEGF in Cancer (36 papers), Cancer Treatment and Pharmacology (20 papers) and Cancer, Hypoxia, and Metabolism (16 papers). Joachim Drevs collaborates with scholars based in Germany, United Kingdom and United States. Joachim Drevs's co-authors include Clemens Unger, Michael Medinger, Felix Kratz, N. Esser, Dieter Marmé, K. Mross, Ute Zirrgiebel, Christine Wittig, Harald Hugenschmidt and Iduna Fichtner and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Joachim Drevs

72 papers receiving 3.2k citations

Peers

Countries citing papers authored by Joachim Drevs

Since Specialization

Citations

This map shows the geographic impact of Joachim Drevs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joachim Drevs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joachim Drevs more than expected).

Fields of papers citing papers by Joachim Drevs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joachim Drevs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joachim Drevs. The network helps show where Joachim Drevs may publish in the future.

Co-authorship network of co-authors of Joachim Drevs

This figure shows the co-authorship network connecting the top 25 collaborators of Joachim Drevs. A scholar is included among the top collaborators of Joachim Drevs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joachim Drevs. Joachim Drevs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment of advanced solid tumours with NSAIDs: Correlation of quantitative monitoring of circulating tumour cells and positron emission tomography-computed tomography imaging 2016 ·Oncology Letters ·(unknown), Katharina Pachmann, Joachim Drevs	2
2	Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors 2011 ·International Journal of Clinical Pharmacology and Therapeutics ·Dirk Strumberg, Beate Schultheis, (unknown), Christiane Vank, Ansgar Santel, Oliver Keil, Klaus Giese, Jörg Kaufmann, Joachim Drevs	112
3	Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma. 2009 ·PubMed ·Michael Medinger, N. Esser, Ute Zirrgiebel, Anderson J. Ryan, Juliane M. Jürgensmeier, Joachim Drevs	15
4	Mode of action and clinical impact of VEGF signaling inhibitors 2009 ·Expert Review of Anticancer Therapy ·(unknown), Joachim Drevs	19
5	A phase I trial assessing the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of single-dose Auron Misheil therapy in healthy male subjects 2009 ·Journal of Clinical Pharmacy and Therapeutics ·Jürgen Scheele, (unknown), Joachim Drevs, (unknown)	0
6	Molecular Targeted Therapies for Solid Tumors: Management of Side Effects 2009 ·Oncology Research and Treatment ·Viktor Grünwald, (unknown), Philipp Ivanyi, (unknown), Christoph Reuter, Joachim Drevs	20
7	Mode-of-Action, Efficacy, and Safety of a Homologous Multi-Epitope Vaccine in a Murine Model for Adjuvant Treatment of Renal Cell Carcinoma 2008 ·European Urology ·Christian Doehn, N. Esser, Hans‐Gerd Pauels, S.T. Kießig, Matthias Stelljes, (unknown), D. Jocham, Joachim Drevs	15
8	Plasma vascular endothelial growth factor and serum soluble angiopoietin receptor sTIE-2 in patients with dural arteriovenous fistulas: a pilot study 2005 ·Neuroradiology ·Joachim Klisch, Ralf Kubalek, (unknown), Ute Zirrgiebel, Joachim Drevs, Martin Schumacher	19
9	Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases 2005 ·Cancer Chemotherapy and Pharmacology ·(unknown), Sunil Sharma, Bruno Morgan, Peter R. Allegrini, Christian Schnell, Josef Brueggen, Robert Cozens, Mark A. Horsfield, (unknown), W P Steward, Joachim Drevs, David Lebwohl, Jeanette M. Wood, Paul M.J. McSheehy	48
10	Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours 2005 ·European Journal of Cancer ·K. Mross, Joachim Drevs, (unknown), Michael Medinger, Dieter Marmé, Jürgen Hennig, Bruno Morgan, David Lebwohl, Eric Masson, (unknown), Clemens Günther, Dirk Laurent, Clemens Unger	129
11	Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials 2005 ·Annals of Oncology ·Joachim Drevs, Ute Zirrgiebel, (unknown), K. Mross, Michael Medinger, (unknown), José Cirı́aco Pinheiro, J M Wood, Anne Thomas, Clemens Unger, Andrew Henry, William P. Steward, Dirk Laurent, David Lebwohl, Margaret Dugan, Dieter Marmé	95
12	Development of Albumin‐binding Doxorubicin Prodrugs that are Cleaved by Prostate‐specific Antigen 2005 ·Archiv der Pharmazie ·Felix Kratz, Ahmed M. Mansour, (unknown), André Warnecke, Iduna Fichtner, Clemens Unger, Joachim Drevs	33
13	Receptor Tyrosine Kinases and Anticancer Therapy 2005 ·Current Pharmaceutical Design ·Michael Medinger, Joachim Drevs	30
14	Receptor Tyrosine Kinases: The Main Targets for New Anticancer Therapy 2003 ·Current Drug Targets ·Joachim Drevs, Michael Medinger, (unknown), Renate Weber, Clemens Unger	60
15	Angiogenesis and the ET-1/ETA Receptor System: Immunohistochemical Expression Analysis in Bone Metastases from Patients with Different Primary Tumors 2003 ·Angiogenesis ·Michael Medinger, C. P. Adler, (unknown), (unknown), (unknown), Clemens Unger, Joachim Drevs	10
16	Surrogate marker in clinical studies with anti-angiogenic drugs 2003 ·International Journal of Clinical Pharmacology and Therapeutics ·Ute Zirrgiebel, Joachim Drevs	3
17	Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours 2003 ·European Journal of Cancer ·Ferry A.L.M. Eskens, Herlinde Dumez, Ronald Hoekstra, (unknown), C. Brindley, Sebastian Böttcher, Wim Wynendaele, Joachim Drevs, Jaap Verweij, A.T. van Oosterom	178
18	Soluble Tie‐2 receptor levels independently predict locoregional recurrence in head and neck squamous cell carcinoma 2002 ·Head & Neck ·Jarrod J. Homer, John Greenman, Joachim Drevs, Dieter Marmé, Nicholas D. Stafford	9
19	In Vivo and In Vitro Efficacy of an Acid-Sensitive Albumin Conjugate of Adriamycin Compared to the Parent Compound in Murine Renal-Cell Carcinoma 1999 ·Drug Delivery ·Joachim Drevs, Inga Hofmann, Dieter Marmé, Clemens Unger, Felix Kratz	12
20	Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine 1994 ·Cancer Chemotherapy and Pharmacology ·Petra Kaufmann‐Kolle, Joachim Drevs, Martin R. Berger, (unknown), Norbert Marschner, Clemens Unger, H. Eibl	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact